VTT and Bayer Schering Pharma will collaborate to study the mode of action of a Bayer’s new cancer drug. As part of this two-year research contract, VTT will use its new gene and cell biology methods.
VTT’s focus is on identifying primary driver genes and targets of genetic alterations in cancer. The company also works toward finding drug compounds preventing the growth and metastasis of breast and prostate cancer.